Sanofi Q4 earnings hit by weak dollar, generic competition

Sanofi's (SASY.PA), fourth-quarter operating income fell 5% as a weaker U.S. dollar and cheap competition to multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent.